
Biolevate is a VC-backed, early-stage B2B startup that leverages GenAI & ML to accelerate therapeutic innovation. Their all-in-one workflow automation SaaS platform helps life science professionals analyze, prioritize, and act on complex biological data faster. The company was founded in 2023 with a belief in a future where healthcare innovations meet ethical AI, enabling simple, secure, and collaborative solutions. Biolevate's powerful features include automated data extraction, predictive analytics, and centralized project management tools designed for compliance, security, and operational efficiency. They focus on solutions for Curation & Screening, Content Generation, and Research & Literature Monitoring, aiming to reduce development costs and time-to-market for new therapies.

Biolevate is a VC-backed, early-stage B2B startup that leverages GenAI & ML to accelerate therapeutic innovation. Their all-in-one workflow automation SaaS platform helps life science professionals analyze, prioritize, and act on complex biological data faster. The company was founded in 2023 with a belief in a future where healthcare innovations meet ethical AI, enabling simple, secure, and collaborative solutions. Biolevate's powerful features include automated data extraction, predictive analytics, and centralized project management tools designed for compliance, security, and operational efficiency. They focus on solutions for Curation & Screening, Content Generation, and Research & Literature Monitoring, aiming to reduce development costs and time-to-market for new therapies.
Headquarters: Paris, France
Founded: 2023
Stage / Funding: Seed — €6M (Nov 2024) led by EQT Ventures
Product focus: AI Knowledge Platform for life sciences (NLP + computer vision) to accelerate scientific & regulatory document workflows
Employees: ~29
Complex biomedical and regulatory documentation workflows (systematic literature review, clinical study report/CTD generation, batch record quality control).
2023
Biotechnology
€6,000,000
Round included participation from Bpifrance and angel investor Mehdi Ghissassi.
“Led by EQT Ventures with participation from Bpifrance and angel investor Mehdi Ghissassi”
Biolevate is a VC-backed B2B early-stage startup harnessing the power of GenAI & ML to deliver therapeutics innovation faster to market through an all-in-one workflow automation SaaS platform. At Biolevate, we value your expertise and creativity, offering you significant autonomy and engaging projects that make a real impact.
Machine Learning Engineer Paris Full-time Engineering